@article{000a711224ff4371ac6492f9a6dcb3e9,
title = "Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults",
abstract = "Objective: To determine the relationship between proton magnetic resonance spectroscopy (1H MRS) metabolites and β-amyloid (Aβ) load and the effects of Aβ load on the association between 1H MRS metabolites and cognitive function in cognitively normal older adults. Methods: We studied 311 cognitively normal older adults who participated in the populationbased Mayo Clinic Study of Aging from January 2009 through September 2010. Participants underwent 11C-Pittsburgh compound B (PiB) PET, 1H MRS from the posterior cingulate gyri, and neuropsychometric testing to assess memory, attention/executive, language, and visual-spatial domain functions within 6 months. Partial Spearman rank order correlations were adjusted for age, sex, and education. Results: Higher PiB retention was associated with abnormal elevations in myoinositol (mI)/creatine (Cr) (partial rs = 0.17; p = 0.003) and choline (Cho)/Cr (partial rs = 0.13; p = 0.022) ratios. Higher Cho/Cr was associated with worse performance on Auditory Verbal Learning Test Delayed Recall (partial rs = -0.12; p = 0.04), Trail Making Test Part B (partial rs = 0.12; p = 0.04), Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol (partial r s = -0.18; p < 0.01), and WAIS-R Block Design (partial r s=-0.12; p = 0.03). Associations between 1H MRS metabolites and cognitive function were not different among participants with high vs low PiB retention. Conclusion: In cognitively normal older adults, the 1H MRS metabolite ratios mI/Cr and Cho/Cr are associated with the preclinical pathologic processes in the Alzheimer disease cascade. Higher Cho/Cr is associated with worse performance on domain-specific cognitive tests independent of Aβ load, suggesting that Cho/Cr elevation may also be dependent on other preclinical dementia pathologies characterized by Cho/Cr elevation such as Lewy body or ischemic vascular disease in addition to Aβ load.",
author = "K. Kantarci and V. Lowe and Przybelski, {S. A.} and Senjem, {M. L.} and Weigand, {S. D.} and Ivnik, {R. J.} and R. Roberts and Geda, {Y. E.} and Boeve, {B. F.} and Knopman, {D. S.} and Petersen, {R. C.} and Jack, {C. R.}",
note = "Funding Information: Dr. Kantarci receives research support from the NIH. Dr. Lowe serves on scientific advisory boards for Bayer Schering Pharma and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, the NIH (NIA, NCI), the MN Partnership for Biotechnology and Medical Genomics, and the Leukemia & Lymphoma Society. S.A. Przybelski reports no disclosures. M.L. Senjem has received research support from Pfizer Inc. S.D. Weigand reports no disclosures. Dr. Ivnik serves on the editorial boards of The Clinical Neuropsychologist and Aging, Neuropsychology, and Cognition ; receives publishing royalties for Clinical Interpretation of the WAIS-III and WMS-III (Academic Press, 2003); and receives research support from the NIH/NIA. Dr. Roberts receives research support from the NIH. Dr. Geda receives research support from the NIH. Dr. Boeve has served as a consultant to GE Healthcare; receives publishing royalties for The Behavioral Neurology of Dementia (Cambridge University Press, 2009); and receives research support from Cephalon, Inc., Allon Therapeutics, Inc., the NIH/NIA, the Alzheimer's Association, and the Mangurian Foundation. Dr. Knopman serves as Deputy Editor for Neurology {\textregistered}; has served on a data safety monitoring board for Eli Lilly and Company; has served as a consultant for Elan/Janssen AI; is an investigator in clinical trials sponsored by Elan/Janssen AI, Baxter International Inc., and Forest Laboratories, Inc.; and receives research support from the NIH. Dr. Petersen serves on scientific advisory boards for the Alzheimer's Association, the National Advisory Council on Aging (NIA), Elan/Janssen AI, Pfizer Inc (Wyeth), and GE Healthcare; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); serves as a consultant for Elan/Janssen AI and GE Healthcare; and receives research support from the NIH/NIA. Dr. Jack serves on scientific advisory boards for Elan/Janssen AI, Eli Lilly & Company, GE Healthcare, and Eisai Inc.; receives research support from Baxter International Inc., Allon Therapeutics, Inc., Pfizer Inc, the NIH/NIA, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation; and holds stock/stock options in Johnson & Johnson.",
year = "2011",
month = sep,
day = "6",
doi = "10.1212/WNL.0b013e31822dc7e1",
language = "English (US)",
volume = "77",
pages = "951--958",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",
}